Results 131 to 140 of about 2,864 (172)

Delamanid

Reactions Weekly, 2021
openaire   +1 more source

Delamanid

Reactions Weekly, 2022
openaire   +1 more source

Delamanid

Reactions Weekly, 2023
openaire   +1 more source

[Expert consensus on clinical application of delamanid].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2022
Multidrug-resistant tuberculosis(MDR-TB) is a major problem in the prevention and treatment of tuberculosis worldwide, but the treatment success rate is low, and it is necessary to develop new anti-tuberculosis drugs and optimize treatment. Delamanid, a drug with good activity against MDR-TB, has been marketed in recent years.
openaire   +1 more source

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Antimicrobial Agents and Chemotherapy, 2022
Tomohiro Sasaki, Elin M Svensson, Jeffrey Hafkin   +2 more
exaly  

Bedaquiline/delamanid

Reactions Weekly, 2019
  +4 more sources

Bedaquiline/delamanid

Reactions Weekly, 2022
openaire   +1 more source

Bedaquiline/delamanid

Reactions Weekly, 2021
openaire   +1 more source

Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid

Clinical Infectious Diseases, 2021
Takashi Yoshiyama, Akio Aono, Satoshi Mitarai   +2 more
exaly  

Bedaquiline/delamanid

Reactions Weekly, 2023
openaire   +1 more source